{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T04:04:37Z","timestamp":1792037077196,"version":"4.4.0"},"reference-count":56,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2017,9,1]],"date-time":"2017-09-01T00:00:00Z","timestamp":1504224000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,9,1]],"date-time":"2017-09-01T00:00:00Z","timestamp":1504224000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"vor","delay-in-days":2679,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["jpet.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"published-print":{"date-parts":[[2017,9]]},"DOI":"10.1124\/jpet.117.241653","type":"journal-article","created":{"date-parts":[[2017,6,23]],"date-time":"2017-06-23T00:30:13Z","timestamp":1498177813000},"page":"413-423","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":83,"title":["Sembragiline: A Novel, Selective Monoamine Oxidase Type B Inhibitor for the Treatment of Alzheimer\u2019s Disease"],"prefix":"10.1016","volume":"362","author":[{"given":"Edilio","family":"Borroni","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernd","family":"Bohrmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fiona","family":"Grueninger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Prinssen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephane","family":"Nave","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hansruedi","family":"Loetscher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shankar J","family":"Chinta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Subramanian","family":"Rajagopalan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anand","family":"Rane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Almas","family":"Siddiqui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bart","family":"Ellenbroek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juerg","family":"Messer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Axel","family":"P\u00e4hler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie K","family":"Andersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rene","family":"Wyler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea M","family":"Cesura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1124\/jpet.117.241653_bib1","series-title":"World Alzheimer's Report 2015: The Global Impact of Dementia. An Analysis of Prevalence, Incidence, Cost and Trends","year":"2015"},{"key":"10.1124\/jpet.117.241653_bib2","series-title":"World Alzheimer's Report 2014: An Analysis of Long-Term Care for Dementia","year":"2013"},{"key":"10.1124\/jpet.117.241653_bib3","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.arr.2014.07.004","article-title":"When astrocytes become harmful: functional and inflammatory responses that contribute to Alzheimer\u2019s disease","volume":"18","author":"Avila-Mu\u00f1oz","year":"2014","journal-title":"Ageing Res Rev"},{"key":"10.1124\/jpet.117.241653_bib4","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/BF00280072","article-title":"Measurement of human cerebral monoamine oxidase type B (MAO-B) activity with positron emission tomography (PET): a dose ranging study with the reversible inhibitor Ro 19-6327","volume":"40","author":"Bench","year":"1991","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1124\/jpet.117.241653_bib5","doi-asserted-by":"crossref","first-page":"3","DOI":"10.2174\/157488707779318107","article-title":"The potential of trace amines and their receptors for treating neurological and psychiatric diseases","volume":"2","author":"Berry","year":"2007","journal-title":"Rev Recent Clin Trials"},{"key":"10.1124\/jpet.117.241653_bib6","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/0014-2999(75)90238-1","article-title":"The monoamine oxidase B inhibitor deprenyl potentiates phenylethylamine behaviour in rats without inhibition of catecholamine metabolite formation","volume":"34","author":"Braestrup","year":"1975","journal-title":"Eur J Pharmacol"},{"key":"10.1124\/jpet.117.241653_bib7","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.3892\/mmr.2014.2040","article-title":"Monoamine oxidase inhibitors: promising therapeutic agents for Alzheimer\u2019s disease (Review)","volume":"9","author":"Cai","year":"2014","journal-title":"review Mol Med Rep"},{"key":"10.1124\/jpet.117.241653_bib8","doi-asserted-by":"crossref","first-page":"37","DOI":"10.2967\/jnumed.110.087031","article-title":"Evidence for astrocytosis in prodromal Alzheimer disease provided by 11C-deuterium-L-deprenyl: a multitracer PET paradigm combining 11C-Pittsburgh compound B and 18F-FDG","volume":"53","author":"Carter","year":"2012","journal-title":"J Nucl Med"},{"key":"10.1124\/jpet.117.241653_bib9","doi-asserted-by":"crossref","first-page":"a020370","DOI":"10.1101\/cshperspect.a020370","article-title":"Astrocytes control synapse formation, function, and elimination","volume":"7","author":"Chung","year":"2015","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"10.1124\/jpet.117.241653_bib10","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1038\/nature12776","article-title":"Astrocytes mediate synapse elimination through MEGF10 and MERTK pathways","volume":"504","author":"Chung","year":"2013","journal-title":"Nature"},{"key":"10.1124\/jpet.117.241653_bib11","doi-asserted-by":"crossref","first-page":"2310","DOI":"10.1046\/j.1471-4159.1999.0732310.x","article-title":"Monoamine oxidase and mitochondrial respiration","volume":"73","author":"Cohen","year":"1999","journal-title":"J Neurochem"},{"key":"10.1124\/jpet.117.241653_bib12","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1006\/abio.1997.2145","article-title":"Microtiter plate assays for inhibition of human, drug-metabolizing cytochromes P450","volume":"248","author":"Crespi","year":"1997","journal-title":"Anal Biochem"},{"key":"10.1124\/jpet.117.241653_bib13","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.immuni.2016.02.013","article-title":"Microglial physiology and pathophysiology: Insights from genome-wide transcriptional profiling","volume":"44","author":"Crotti","year":"2016","journal-title":"Immunity"},{"key":"10.1124\/jpet.117.241653_bib14","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1016\/S1474-4422(16)00127-7","article-title":"Genetic variations underlying Alzheimer\u2019s disease: evidence from genome-wide association studies and beyond","volume":"15","author":"Cuyvers","year":"2016","journal-title":"Lancet Neurol"},{"key":"10.1124\/jpet.117.241653_bib15","first-page":"279","article-title":"From moclobemide to ro 19-6327 and ro 41-1049: The development of a new class of reversible, selective MAO-A and MAO-B inhibitors","volume":"29","author":"Da Prada","year":"1990","journal-title":"J Neural Transm Suppl"},{"key":"10.1124\/jpet.117.241653_bib16","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/BF00426954","article-title":"Deprenyl administration in man: a selective monoamine oxidase B inhibitor without the \u2018cheese effect\u2019","volume":"57","author":"Elsworth","year":"1978","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1124\/jpet.117.241653_bib17","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/S0304-3940(02)00307-5","article-title":"Increased monoamine oxidase messenger RNA expression levels in frontal cortex of Alzheimer\u2019s disease patients","volume":"326","author":"Emilsson","year":"2002","journal-title":"Neurosci Lett"},{"key":"10.1124\/jpet.117.241653_bib18","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/s10048-014-0409-x","article-title":"\u2018Neuroinflammation\u2019 differs categorically from inflammation: transcriptomes of Alzheimer\u2019s disease, Parkinson\u2019s disease, schizophrenia and inflammatory diseases compared","volume":"15","author":"Filiou","year":"2014","journal-title":"Neurogenetics"},{"key":"10.1124\/jpet.117.241653_bib19","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1002\/syn.890180203","article-title":"Slow recovery of human brain MAO B after L-deprenyl (Selegeline) withdrawal","volume":"18","author":"Fowler","year":"1994","journal-title":"Synapse"},{"key":"10.1124\/jpet.117.241653_bib20","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1016\/j.biopsych.2005.11.016","article-title":"A review of serotonin toxicity data: implications for the mechanisms of antidepressant drug action","volume":"59","author":"Gillman","year":"2006","journal-title":"Biol Psychiatry"},{"key":"10.1124\/jpet.117.241653_bib21","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1177\/0091270010369674","article-title":"Clinical pharmacology tyramine challenge study to determine the selectivity of the monoamine oxidase type B (MAO-B) inhibitor rasagiline","volume":"50","author":"Goren","year":"2010","journal-title":"J Clin Pharmacol"},{"key":"10.1124\/jpet.117.241653_bib22","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.neuint.2010.10.013","article-title":"Activated MAO-B in the brain of Alzheimer patients, demonstrated by [11C]-L-deprenyl using whole hemisphere autoradiography","volume":"58","author":"Guly\u00e1s","year":"2011","journal-title":"Neurochem Int"},{"key":"10.1124\/jpet.117.241653_bib23","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1111\/j.1365-2125.1994.tb04303.x","article-title":"Pharmacodynamics of lazabemide, a reversible and selective inhibitor of monoamine oxidase B","volume":"37","author":"Holford","year":"1994","journal-title":"Br J Clin Pharmacol"},{"key":"10.1124\/jpet.117.241653_bib24","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/0024-3205(76)90303-9","article-title":"An animal behavior model for studying central serotonergic synapses","volume":"19","author":"Jacobs","year":"1976","journal-title":"Life Sci"},{"key":"10.1124\/jpet.117.241653_bib25","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1038\/nm.3639","article-title":"GABA from reactive astrocytes impairs memory in mouse models of Alzheimer\u2019s disease","volume":"20","author":"Jo","year":"2014","journal-title":"Nat Med"},{"key":"10.1124\/jpet.117.241653_bib26","doi-asserted-by":"crossref","first-page":"h369","DOI":"10.1136\/bmj.h369","article-title":"Assessment and management of behavioral and psychological symptoms of dementia","volume":"350","author":"Kales","year":"2015","journal-title":"BMJ"},{"key":"10.1124\/jpet.117.241653_bib27","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1007\/s00702-003-0828-6","article-title":"Early and persistent alterations in prefrontal cortex MAO A and B in Alzheimer\u2019s disease","volume":"110","author":"Kennedy","year":"2003","journal-title":"J Neural Transm (Vienna)"},{"key":"10.1124\/jpet.117.241653_bib28","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.3233\/JAD-142952","article-title":"Concordance and diagnostic accuracy of [11C]PIB PET and cerebrospinal fluid biomarkers in a sample of patients with mild cognitive impairment and alzheimer\u2019s disease","volume":"45","author":"Leuzy","year":"2015","journal-title":"J Alzheimers Dis"},{"key":"10.1124\/jpet.117.241653_bib29","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1038\/nature21029","article-title":"Neurotoxic reactive astrocytes are induced by activated microglia","volume":"541","author":"Liddelow","year":"2017","journal-title":"Nature"},{"issue":"Suppl 5","key":"10.1124\/jpet.117.241653_bib30","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/S0924-977X(99)80017-0","article-title":"Lazabemide for the long-term treatment of alzheimer\u2019s disease","volume":"9","author":"Magni","year":"1999","journal-title":"Eur Neuropsychopharmacol"},{"key":"10.1124\/jpet.117.241653_bib31","doi-asserted-by":"crossref","first-page":"e1616","DOI":"10.1371\/journal.pone.0001616","article-title":"MAO-B elevation in mouse brain astrocytes results in Parkinson\u2019s pathology","volume":"3","author":"Mallajosyula","year":"2008","journal-title":"PLoS One"},{"key":"10.1124\/jpet.117.241653_bib32","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1006\/nbdi.2002.0507","article-title":"Environmental risk factors and Parkinson\u2019s disease: selective degeneration of nigral dopaminergic neurons caused by the herbicide paraquat","volume":"10","author":"McCormack","year":"2002","journal-title":"Neurobiol Dis"},{"key":"10.1124\/jpet.117.241653_bib33","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.jalz.2011.03.005","article-title":"The diagnosis of dementia due to Alzheimer\u2019s disease: recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease","volume":"7","author":"McKhann","year":"2011","journal-title":"Alzheimers Dement"},{"key":"10.1124\/jpet.117.241653_bib34","doi-asserted-by":"crossref","first-page":"59","DOI":"10.3389\/fnint.2013.00059","article-title":"Inflammatory process in alzheimer\u2019s disease","volume":"7","author":"Meraz-R\u00edos","year":"2013","journal-title":"Front Integr Nuerosci"},{"key":"10.1124\/jpet.117.241653_bib35","doi-asserted-by":"crossref","first-page":"716","DOI":"10.18632\/aging.100361","article-title":"Polyamines in aging and disease","volume":"3","author":"Minois","year":"2011","journal-title":"Aging (Albany NY)"},{"key":"10.1124\/jpet.117.241653_bib36","doi-asserted-by":"crossref","unstructured":"Nave S, Doody RS, Boada M, Grimmer T, Savola JM, Delmar P, Pauly-Evers M, Nikolcheva T, Czech C, Borroni E, et al. (2017) Sembragiline in moderate Alzheimer\u2019s disease: Results of a randomized, double-blind, placebo-controlled phase 2 trial (MAyflOwer RoAD). J Alzheimers Dis, in press.","DOI":"10.3233\/JAD-161309"},{"key":"10.1124\/jpet.117.241653_bib37","first-page":"201","article-title":"Platelet MAO-B activity as a marker of behavioural characteristics in dementia disorders","volume":"6","author":"Parnetti","year":"1994","journal-title":"Aging (Milano)"},{"key":"10.1124\/jpet.117.241653_bib38","first-page":"219","article-title":"Studies on free radicals, antioxidants, and co-factors","volume":"2","author":"Rahman","year":"2007","journal-title":"Clin Interv Aging"},{"key":"10.1124\/jpet.117.241653_bib39","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/S0197-4580(88)80061-7","article-title":"Dopaminergic system and monoamine oxidase-B activity in Alzheimer\u2019s disease","volume":"9","author":"Reinikainen","year":"1988","journal-title":"Neurobiol Aging"},{"key":"10.1124\/jpet.117.241653_bib40","doi-asserted-by":"crossref","first-page":"8989","DOI":"10.1523\/JNEUROSCI.23-26-08989.2003","article-title":"PS2APP transgenic mice, coexpressing hPS2mut and hAPPswe, show age-related cognitive deficits associated with discrete brain amyloid deposition and inflammation","volume":"23","author":"Richards","year":"2003","journal-title":"J Neurosci"},{"key":"10.1124\/jpet.117.241653_bib41","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S0161-813X(03)00106-2","article-title":"Monoamine oxidase-B inhibition in Alzheimer\u2019s disease","volume":"25","author":"Riederer","year":"2004","journal-title":"Neurotoxicology"},{"key":"10.1124\/jpet.117.241653_bib42","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1111\/j.1471-4159.1986.tb01747.x","article-title":"Monoamine oxidase activity and monoamine metabolism in brains of parkinsonian patients treated with l-deprenyl","volume":"46","author":"Riederer","year":"1986","journal-title":"J Neurochem"},{"key":"10.1124\/jpet.117.241653_bib43","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1056\/NEJM199704243361704","article-title":"A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer\u2019s disease. The Alzheimer\u2019s Disease Cooperative Study","volume":"336","author":"Sano","year":"1997","journal-title":"N Engl J Med"},{"key":"10.1124\/jpet.117.241653_bib44","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/0306-4522(94)90311-5","article-title":"Increased monoamine oxidase B activity in plaque-associated astrocytes of Alzheimer brains revealed by quantitative enzyme radioautography","volume":"62","author":"Saura","year":"1994","journal-title":"Neuroscience"},{"key":"10.1124\/jpet.117.241653_bib45","doi-asserted-by":"crossref","first-page":"595","DOI":"10.15252\/emmm.201606210","article-title":"The amyloid hypothesis of Alzheimer\u2019s disease at 25\u00a0years","volume":"8","author":"Selkoe","year":"2016","journal-title":"EMBO Mol Med"},{"key":"10.1124\/jpet.117.241653_bib46","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.nbd.2010.12.014","article-title":"Ability to delay neuropathological events associated with astrocytic MAO-B increase in a Parkinsonian mouse model: implications for early intervention on disease progression","volume":"43","author":"Siddiqui","year":"2011","journal-title":"Neurobiol Dis"},{"key":"10.1124\/jpet.117.241653_bib47","first-page":"437","article-title":"Central effects of Ro 19-6327 given acutely and repeatedly","volume":"43","author":"Skuza","year":"1991","journal-title":"Pol J Pharmacol Pharm"},{"key":"10.1124\/jpet.117.241653_bib48","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1016\/j.tins.2009.08.002","article-title":"Molecular dissection of reactive astrogliosis and glial scar formation","volume":"32","author":"Sofroniew","year":"2009","journal-title":"Trends Neurosci"},{"key":"10.1124\/jpet.117.241653_bib49","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1007\/s00259-016-3510-6","article-title":"Positron emission tomography measurement of brain MAO-B inhibition in patients with Alzheimer\u2019s disease and elderly controls after oral administration of sembragiline","volume":"44","author":"Sturm","year":"2017","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1124\/jpet.117.241653_bib50","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/S0197-4580(00)00100-7","article-title":"Monoamine oxidase-B inhibitors in the treatment of Alzheimer\u2019s disease","volume":"21","author":"Thomas","year":"2000","journal-title":"Neurobiol Aging"},{"key":"10.1124\/jpet.117.241653_bib51","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1586\/ern.09.106","article-title":"What is the association between depression and Alzheimer\u2019s disease?","volume":"9","author":"Tsuno","year":"2009","journal-title":"Expert Rev Neurother"},{"key":"10.1124\/jpet.117.241653_bib52","first-page":"1005","article-title":"Inflammation in Alzheimer disease: driving force, bystander or beneficial response?","volume":"12","author":"Wyss-Coray","year":"2006","journal-title":"Nat Med"},{"key":"10.1124\/jpet.117.241653_bib53","doi-asserted-by":"crossref","first-page":"4951","DOI":"10.1113\/jphysiol.2014.278754","article-title":"Glial GABA, synthesized by monoamine oxidase B, mediates tonic inhibition","volume":"592","author":"Yoon","year":"2014","journal-title":"J Physiol"},{"key":"10.1124\/jpet.117.241653_bib54","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1038\/nrn1883","article-title":"The therapeutic potential of monoamine oxidase inhibitors","volume":"7","author":"Youdim","year":"2006","journal-title":"Nat Rev Neurosci"},{"issue":"Suppl 1","key":"10.1124\/jpet.117.241653_bib55","doi-asserted-by":"crossref","first-page":"S8","DOI":"10.1002\/mds.870080504","article-title":"The relevance of glial monoamine oxidase-B and polyamines to the action of selegiline in Parkinson\u2019s disease","volume":"8","author":"Youdim","year":"1993","journal-title":"Mov Disord"},{"key":"10.1124\/jpet.117.241653_bib56","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1006\/abio.1997.2392","article-title":"A one-step fluorometric method for the continuous measurement of monoamine oxidase activity","volume":"253","author":"Zhou","year":"1997","journal-title":"Anal Biochem"}],"container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356524196255?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356524196255?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/jpet.117.241653","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T15:57:06Z","timestamp":1739980626000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022356524196255"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,9]]},"references-count":56,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2017,9]]}},"alternative-id":["S0022356524196255"],"URL":"https:\/\/doi.org\/10.1124\/jpet.117.241653","relation":{},"ISSN":["0022-3565"],"issn-type":[{"value":"0022-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2017,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Sembragiline: A Novel, Selective Monoamine Oxidase Type B Inhibitor for the Treatment of Alzheimer\u2019s Disease","name":"articletitle","label":"Article Title"},{"value":"The Journal of Pharmacology and Experimental Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/jpet.117.241653","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 by The Author(s)","name":"copyright","label":"Copyright"}]}}